Conference item
Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 316.1KB, Terms of use)
-
- Publisher copy:
- 10.1136/annrheumdis-2020-eular.3463
Authors
- Publisher:
- Elsevier
- Host title:
- ANNALS OF THE RHEUMATIC DISEASES
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 79
- Pages:
- 998-998
- Publication date:
- 2020-06-02
- Acceptance date:
- 2020-03-30
- Event title:
- EULAR Congress
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Keywords:
- Pubs id:
-
1127575
- Local pid:
-
pubs:1127575
- Deposit date:
-
2020-09-03
- ARK identifier:
Terms of use
- Copyright holder:
- Prats-Uribe et al.
- Copyright date:
- 2020
- Rights statement:
- © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
- Notes:
- This is the accepted manuscript version of the article. The final version is available from BMJ Journals at: http://dx.doi.org/10.1136/annrheumdis-2020-eular.3463
If you are the owner of this record, you can report an update to it here: Report update to this record